{{expand|time=2015-10-22T10:46:19+00:00}}
{{medical}}{{Infobox drug
| verifiedrevid = 461115603
| IUPAC_name = 1-(aminomethyl)cyclohexaneacetic acid
| drug_name = 加巴噴丁<br>(Gabapentin)
| image = Gabapentin2DACS.svg
| width = 170
| image2 = Gabapentin 3D.png
| width2 = 150px

<!--Clinical data-->
| tradename = Neurontin, others<ref name=drugs.com>[http://www.drugs.com/international/gabapentin.html Drugs.com international listings for Gabapentin] Page accessed Feb. 9, 2016</ref>
| Drugs.com = {{drugs.com|monograph|gabapentin}}
| MedlinePlus = a694007
| DailyMedID = 52049
| licence_US = Gabapentin
| pregnancy_AU = B1
| pregnancy_US = C
| pregnancy_category =
| legal_AU = S4
| legal_CA = Rx-only
| legal_US = Rx-only
| legal_UK = POM
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 27-60% （与剂量成反比; 高脂饮食会提高生物利用度）<ref name = MSR>{{cite web|title=Neurontin, Gralise (gabapentin) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=6 April 2014|url=http://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011#showall}}</ref><ref name = drugs93>{{cite journal|last=Goa|first=KL|author2=Sorkin, EM|title=Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.|journal=Drugs|date=September 1993|volume=46|issue=3|pages=409–27|doi=10.2165/00003495-199346030-00007|pmid=7693432}}</ref>
| protein_bound = 低於 3%<ref name = MSR/><ref name = drugs93/>
| metabolism = 不被明顯代謝<ref name = MSR/><ref name = drugs93/>
| elimination_half-life = 5 至 7 小時<ref name = MSR/><ref name = drugs93/>
| excretion = [[腎臟|腎臟]]<ref name = MSR/><ref name = drugs93/>

<!--Identifiers -->
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6CW7F3G59X
| InChI = 1/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
| InChIKey = UGJMXCAKCUNAIE-UHFFFAOYAG
| ChEBI_Ref = {{ebicite|correct|EBI}} 
| ChEBI = 42797
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 940
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UGJMXCAKCUNAIE-UHFFFAOYSA-N
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 60142-96-3
| ATC_prefix = N03
| ATC_suffix = AX12
| PubChem = 3446
| IUPHAR_ligand = 5483
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00996
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3328
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00332
| PDB_ligand = GBN

<!--Chemical data-->
| chemical_formula =
| C=9 | H=17 | N=1 | O=2
| molecular_weight = 171.237 g/mol
| smiles = O=C(O)CC1(CN)CCCCC1
}}


<!-- 定義與醫療用途 -->
'''加巴喷丁（{{lang-la|Gabapentin}}）'''，研發廠商品名為Neurontin，用於治療 [[癫痫|癫痫]]、{{tsl|en|neuropathic pain|神經性疼痛|神經痛}}、[[潮熱|潮熱]]、以及[[睡眠腳動症|睡眠腳動症]]<ref name=AHFS2015>{{cite web|title=Gabapentin|url=http://www.drugs.com/monograph/gabapentin.html|publisher=The American Society of Health-System Pharmacists|accessdate=Oct 23, 2015}}</ref><ref>{{cite journal|last1=Wijemanne|first1=S|last2=Jankovic|first2=J|title=Restless legs syndrome: clinical presentation diagnosis and treatment.|journal=Sleep medicine|date=June 2015|volume=16|issue=6|pages=678-90|doi=10.1016/j.sleep.2015.03.002|pmid=25979181}}</ref>。這種藥物一般用於治療 {{tsl|en|partial seizures||癲癇小發作}}，<ref name=Attal2010>{{cite journal  |vauthors=Attal N, Cruccu G, Baron R, etal |title=EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision |journal=Eur. J. Neurol. |volume=17 |issue=9 |pages=1113–e88 |date=September 2010 |pmid=20402746 |doi=10.1111/j.1468-1331.2010.02999.x |url=}}</ref>加巴噴丁也是治療 {{tsl|en|diabetic neuropathy|糖尿病神經炎|糖尿病神經炎}}、{{tsl|en|post-herpetic neuralgia|皰疹後的劇痛|皰疹後的劇痛}}、以及{{tsl|en|central neuropathic pain||central neuropathic pain}}等疾病的神經性病痛的首選<ref name=Attal2010>{{cite journal  |vauthors=Attal N, Cruccu G, Baron R, etal |title=EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision |journal=Eur. J. Neurol. |volume=17 |issue=9 |pages=1113–e88 |date=September 2010 |pmid=20402746 |doi=10.1111/j.1468-1331.2010.02999.x |url=}}</ref>，約14%神經性病變疼痛的患者可獲得改善<ref name=Moore2014>{{cite journal|last1=Moore|first1=RA|last2=Wiffen|first2=PJ|last3=Derry|first3=S|last4=Toelle|first4=T|last5=Rice|first5=AS|title=Gabapentin for chronic neuropathic pain and fibromyalgia in adults.|journal=The Cochrane database of systematic reviews|date=27 April 2014|volume=4|pages=CD007938|pmid=24771480}}</ref>。

<!-- 副作用與機制 -->
副作用包含嗜睡和[[暈眩|暈眩]]<!-- <ref name=AHFS2015/> -->。嚴重的副作用可能包含提高[[自殺|自殺]]風險、躁動行為以及{{tsl|en|drug reaction with eosinophilia and systemic symptoms|嗜酸粒細胞增多以及全身性症狀|嗜酸粒細胞增多以及全身性症狀}}<ref name=AHFS2015/> 。對於[[妊娠|妊娠]]或[[母乳餵養|母乳餵養]]是否有危害尚不明確<ref>{{cite web|title=Gabapentin Pregnancy and Breastfeeding Warnings|url=http://www.drugs.com/pregnancy/gabapentin.html|accessdate=13 March 2016}}</ref>。[[腎功能衰竭|腎功能衰竭]]患者應使用較低劑量<!-- <ref name=AHFS2015/> -->。加巴噴丁會對抑制性的神經傳遞物[[Γ-氨基丁酸|Γ-氨基丁酸]] (GABA) 有所影響，但它的作用方式尚無定論<ref name=AHFS2015/>。

<!-- 歷史、社會、與文化 -->
加巴噴丁在1993年首次通過[[美国食品药品监督管理局|美国食品药品监督管理局]]批准<ref>{{cite web|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020235}}</ref><ref>{{cite book|last1=Pitkänen|first1=Asla|last2=Schwartzkroin|first2=Philip A.|last3=Moshé|first3=Solomon L.|title=Models of Seizures and Epilepsy.|date=2005|publisher=Elsevier|location=Burlington|isbn=9780080457024|page=539|url=https://books.google.ca/books?id=Qw6KqLjwtZQC&pg=PA539}}</ref>。批價約在每日1.35美元<ref>{{cite web|title=Gabapentin|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=GAB400T&s_year=2014&year=2014&str=400%20mg&desc=Gabapentin&pack=new&frm=TAB-CAP&rte=PO&class_code2=05%2E&supplement=&class_name=%2805%2E%29Anticonvulsants%2Fantiepileptics%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=13 March 2016}}{{dead link|date=2018年5月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>。在美國，此藥從2004年開始已經可以[[通用名药物|通用名药物]]的方式取得<ref name=AHFS2015/>，2015年，在美國一個月的藥物成本在100到200美金間<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=327}}</ref>。1990年代，{{tsl|en|Parke-Davis|派德藥廠|派德藥廠}}（[[輝瑞|輝瑞]]的子公司之一）透過一系列的手法，鼓勵美國的醫生對加巴噴丁進行{{tsl|en|off-label use|非常規使用|非常規的使用}}<ref name="pmid16908923">{{cite journal| author=Henney JE| title = Safeguarding patient welfare: who's in charge?| journal={{tsl|en|Annals of Internal Medicine||Annals of Internal Medicine}}| volume = 145| issue = 4| pages = 305–7| date=August 2006 | pmid = 16908923| url = http://www.annals.org/content/145/4/305.full.pdf| doi=10.7326/0003-4819-145-4-200608150-00013}}</ref>。

==引用==
{{reflist}}

==外部連結==
* [http://www.drugbank.ca/drugs/DB00996 DrugBank: gabapentin]
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694007.html Gabapentin information from MedlinePlus]
* [http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000940/ "Gabapentin"] PubMed Health. National Center for Biotechnology Information (NCBI)
* [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm "Suicidal Behavior and Ideation and Antiepileptic Drugs"] [[Food_and_Drug_Administration|U.S. Food and Drug Administration]] (FDA)
* [http://topics.nytimes.com/topics/news/health/diseasesconditionsandhealthtopics/neurontin_drug/ Neurontin] collected news and commentary at ''[[The_New_York_Times|The New York Times]]''
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Gabapentin "Gabapentin"] Drug Information Portal. U.S. National Library of Medicine.

{{抗癫痫药}}
{{Anxiolytics}}
{{Hypnotics and sedatives}}

[[Category:氨基酸|Category:氨基酸]]
[[Category:止痛药|Category:止痛药]]
[[Category:抗痉挛药物|Category:抗痉挛药物]]
[[Category:抗焦虑药|Category:抗焦虑药]]
[[Category:钙通道阻滞药|Category:钙通道阻滞药]]
[[Category:氨基丁酸类似物|Category:氨基丁酸类似物]]
[[Category:輝瑞產品|Category:輝瑞產品]]